CYP2C8 and SLCO1B1 Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes.

Diabetes Care 2016 Nov 6;39(11):1902-1908. Epub 2016 Jun 6.

Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee, Scotland

Objective: Thiazolidinediones (TZDs) are putatively transported into the liver by OATP1B1 (encoded by SLCO1B1) and metabolized by CYP450 2C8 enzyme (encoded by CYP2C8). While CYP2C8*3 has been shown to alter TZD pharmacokinetics, it has not been shown to alter efficacy.

Research Design And Methods: We genotyped 833 Scottish patients with type 2 diabetes treated with pioglitazone or rosiglitazone and jointly investigated association of variants in these two genes with therapeutic outcome.

Results: The CYP2C8*3 variant was associated with reduced glycemic response to rosiglitazone (P = 0.01) and less weight gain (P = 0.02). The SLCO1B1 521T>C variant was associated with enhanced glycemic response to rosiglitazone (P = 0.04). The super responders defined by combined genotypes at CYP2C8 and SLCO1B1 had a 0.39% (4 mmol/mol) greater HbA reduction (P = 0.006) than the poor responders. Neither of the variants had a significant impact on pioglitazone response.

Conclusions: These results show that variants in CYP2C8 and SLCO1B1 have a large clinical impact on the therapeutic response to rosiglitazone and highlight the importance of studying transporter and metabolizing genes together in pharmacogenetics.

Download full-text PDF

Source
http://dx.doi.org/10.2337/dc15-2464DOI Listing
November 2016
17 Reads

Publication Analysis

Top Keywords

response rosiglitazone
12
cyp2c8 slco1b1
12
therapeutic response
8
patients type
8
type diabetes
8
glycemic response
8
variant associated
8
rosiglitazone 001
4
reduced glycemic
4
001 weight
4
gain 002
4
associated enhanced
4
enhanced glycemic
4
rosiglitazone 004
4
521t>c variant
4
slco1b1 521t>c
4
associated reduced
4
002 slco1b1
4
weight gain
4
outcomeresults cyp2c8*3
4

Similar Publications